U.S. FDA approves Wegovy weight-loss pill in industry first
Global News
The approval gives Novo Nordisk a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly.
The U.S. Food and Drug Administration approved Novo Nordisk’s weight-loss pill on Monday, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly.
The pill is 25 milligrams of semaglutide, the same active ingredient in injectable Wegovy and Ozempic, and will be sold under the brand name Wegovy. Novo already sells an oral semaglutide for type 2 diabetes, Rybelsus.
The approval could help spur a turnaround for Novo after a rocky year of sliding shares, profit warnings and slowing sales of its injectable Wegovy amid intense competition from Lilly and pressure from compounded versions.
U.S.-listed shares of Novo jumped 6% in extended trading after the approval announcement.
A 64-week, late-stage study showed participants who took 25 mg of oral semaglutide once daily lost an average of 16.6% of their body weight, compared with 2.7% for those on a placebo.
The pill was approved for chronic weight management in adults with obesity or overweight and at least one related health condition, broadening the potential patient pool at a time when insurers, employers and governments are wrestling with spiraling healthcare costs related to obesity.
It could help open the door to tens of millions of untapped patients in a global market, forecast to be worth some $150 billion a year by next decade.
“You’re going to see a huge uptake in the patient base as new indications open up and as oral versions hit the market,” said Anand Iyer, Chief AI Officer at telehealth firm Welldoc.
Alberta's provincial government has announced the creation of three new all-season resort areas that it claims could generate thousands of jobs and billions in economic benefits.
Corb Lund says he's seeking the intervention as new coal mines could threaten land and water on the eastern slopes of the Rocky Mountains and affect the Prairies downstream.
Officers had recently captured four grizzly bears, but forensic results came back to confirm that none of the bears, an adult female and three young, were linked to the attack.
The research recommends occipital nerve blocks should be offered in emergency rooms to treat acute migraine attacks.
A federal vaccine advisory committee voted on Friday to end the longstanding recommendation that all U.S. babies get the hepatitis B vaccine on the day they’re born.
Darlene Hensch, who once struggled with unexplained infertility, is now expecting quadruplets and preparing for a high-risk delivery and life-changing journey.
Negotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving forward.
They've been married for 55 years, but for most of that time, something has been missing from Janet and Robert Cockwill's life, until their grandson made a remarkable discovery.
NDP interim leader Don Davies said the government's response to a commissioned report on the program was 'shockingly dismissive,' and the health minister has not committed to act.
The Ford government is routinely making decisions before environmental consultations have concluded and under-resourcing public education about those consultations, the AG found.
From 2016 to 2024, the vacancy rate for health-related occupations nearly tripled, increasing from 2.1 per cent to 5.8 per cent, the report said.
The milestone deal with Ottawa signed earlier this week clears regulatory hurdles for a potential pipeline from Alberta to the West Coast.
Canadian veterinarians are sounding the alarm about their loss of access to about 40 per cent of medications they once were able to use and they are blaming Health Canada.